Skip to main content

Aetna to Cover ThyroSeq Thyroid Nodule Test

NEW YORK (GenomeWeb) – ThyroSeq announced today that its ThyroSeq thyroid genomic classifier has received a positive coverage decision from Aetna.

The next-generation sequencing-based test — now in its third version — is designed to analyze a panel of 112 genes, to help physicians diagnose thyroid nodules that have indeterminate fine-needle aspiration cytology, and also provides prognostic information that can guide the treatment of cancerous nodules. It was developed by the University of Pittsburgh Medical Center, which partnered with Sonic Healthcare to form ThyroSeq.

With Aetna's decision, the genomic classifier will be available to the payor's more than 19 million members, ThyroSeq said.